Crypto derivatives should be banks’ ‘gateway drug’ to spot: B2C2
Improved spot market liquidity means cash-settled derivatives shouldn’t be the end goal, says co-founder
Cash-settled crypto derivatives should not be the end goal for banks, according to one of the founders of crypto market-maker B2C2; rather they should be a “gateway drug” to trade the physical product, for which liquidity conditions have improved significantly.
Banks including Goldman Sachs and Nomura have been among the traditional finance world’s first movers in trading bitcoin futures and non-deliverable forwards, while several other futures commission merchants (FCMs) have offered clearing
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact customer services - www.fx-markets.com/static/contact-us, or view our subscription options here: https://subscriptions.fx-markets.com/subscribe
You are currently unable to print this content. Please contact customer services - www.fx-markets.com/static/contact-us to find out more.
You are currently unable to copy this content. Please contact [email protected] to find out more.
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email [email protected]
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email [email protected]
More on Trading
Follow Topics
Receive the content you need straight to your inbox
Choose to follow a range of topics and receive a regular roundup of the latest coverage.